Icon (ICLR) Lifted to “Sell” at BidaskClub
Icon (NASDAQ:ICLR) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Friday.
Several other brokerages have also recently issued reports on ICLR. Barclays boosted their price objective on shares of Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Friday, October 27th. SunTrust Banks reissued a “buy” rating and set a $138.00 price objective on shares of Icon in a research note on Sunday, October 29th. Zacks Investment Research cut shares of Icon from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. KeyCorp reissued a “buy” rating and set a $130.00 price objective on shares of Icon in a research note on Thursday, January 11th. Finally, Robert W. Baird reissued a “buy” rating and set a $123.00 price objective on shares of Icon in a research note on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Icon has a consensus rating of “Buy” and a consensus price target of $124.55.
Shares of Icon (ICLR) opened at $105.67 on Friday. Icon has a 12 month low of $76.46 and a 12 month high of $124.48. The company has a market cap of $5,741.74, a P/E ratio of 20.48, a price-to-earnings-growth ratio of 1.49 and a beta of 0.48. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.